Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
Phase: PHASE3
Conditions: Cutaneous Malignant Melanoma
Sponsor: Universitaire Ziekenhuizen KU Leuven

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 1 of 52 
# 
 
THE ViDMe STUDY 
 
 
Vitamin D supplementation in cutaneous malignant melanoma 
outcome 
 
 
Sponsor: 
University Hospitals Leuven 
 
 
Coordinating Investigator: 
Prof. Marjan Garmyn 
 
Eudract No: 2012-002125-30 
Sponsor's Protocol Code Number 2012LRDVDCM 
 
 
 
 
 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 2 of 52 
# 
 
The information provided in this document is confidential and may not be disclosed without authorization of the sponsor. 
PROTOCOL SYNOPSIS 
Title 
The ViDMe Project 
"Vitamin 
D 
supplementation 
in 
cutaneous 
malignant 
melanoma outcome" 
EudraCT No. 
2012-002125-30 
Phase 
III 
Sponsor 
UZ Leuven 
Coordinating 
Investigator 
Prof M. Garmyn 
Study Objectives 
To assess whether vitamin D supplementation, in the follow 
up period after diagnosis and surgery of the primary tumor, 
has a protective effect on relapse of cutaneous malignant 
melanoma and whether this protective effect correlates with 
vitamin D levels in serum and vitamin D receptor (VDR) 
immunoreactivity in the primary tumor. 
Design 
double-blind randomized placebo-controlled study 
Treatment Groups 
Group 1: optimal standard of care (control group) 
Group 2: high dose vitamin D3 supplementation added on top 
of optimal standard of care. 
Patients will be randomised to treatment or control group in a 
1:1 ratio.  

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 3 of 52 
# 
 
Study Flow 
and Assessments 
The study is divided into three parts: 
• 
Screening 
phase: 
Patients 
are 
recruited 
at 
the 
Departments of Dermatology, Oncosurgery or Medical 
Oncology at the University Hospitals Leuven (Belgium), 
and other European academic sites.If all eligibility criteria 
are met, patients are then randomized to the treatment or 
control group. Randomisation is completed via IVRS. 
Patients are randomized as they come. 
• 
Treatment phase: Vitamin D3 supplementation is given to 
the patients assigned to the treatment group and placebo 
to the control group in a double blind manner. Every 
participant is expected to take in the study drug orally 
once each month. Study duration is a maximum of 3.5 
years or until relapse occurs. 
• 
Follow-up phase: Every participant will be followed up 
every 3 months up to the final study visit. Endpoints will 
be reported as occurring throughout the follow up. 
Defined endpoints are adjudicated by an independent 
Clinical Endpoint Committee (CEC) blinded to the patient 
treatment allocation. This ensures a consistent and 
unbiased adjudication of events. 
Study data are reviewed by a Data and Safety Monitoring 
Board (DSMB) that reviews key safety data on an ongoing 
basis.  

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 4 of 52 
# 
Therapy 
Ampoules of 100 000 IE cholecalciferol (vitamin D3) are 
prepared by the pharmacist and will be taken orally at a 
monthly basis. Duration of the treatment: till the end of the 
study (max 3.5 years) or until relapse. Placebo capsules, 
consisting of oil preparation will be prepared in the same way. 
All patients are treated with optimal standard cutaneous 
melanoma follow-up. 
Population 
Adult male or female patients with histologically diagnosed 
stage IB to III cutaneous melanoma are eligible for the trial. 
Inclusion Criteria 
1. 
Older than 18 years and younger than 80 years of age. 
2. 
Histologically proven malignant melanoma, stage IB to 
III Not participating in other clinical trial. 
3. 
The only treatment for melanoma is surgical treatment. 
4. 
Complete resection of melanoma. 
5. 
Single primary invasive cutaneous melanoma 
(inclusion within 1 year after diagnosis). 
6. 
Signed ethical committee approved informed consent 
7. 
Serum phosphate and calcium at the entry of the 
study within normal range of the laboratory reference 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 5 of 52 
# 
Exclusion Criteria 
1. 
Pregnant/lactating women or planning on becoming 
pregnant during the study  
2. 
Known hypersensitivity to vitamin D or its 
components. 
3. 
Pre-existing renal stone disease or chronic renal 
disease with eGRF < 30 mL/min/1.73 m2 or renal dialysis. 
4. 
Liver failure or chronic liver disease with liver enzyme 
> 2 fold ULN (=upper limit of normal) 
5. 
History of parathyroid disease or granulomatous 
disease (TBC and sarcoidosis) 
6. 
History of malabsorption syndrome or any medical 
condition that might interfere with vitamin D absorption. 
7. 
History of other malignancy  within the last 5 years 
except for carcinoma in situ of the cervix or basal cell 
carcinoma or squamous cell carcinoma of the skin or in situ 
malignant melanoma. 
8. 
Chronic alcohol abuse. 
9. 
Medical or logistic problems likely to preclude 
completion of the study. 
 
Study duration 
Patients are enrolled during a recruitment phase of three 
years maximum. Study duration for one patient is maximum 
3.5 years or until relapse occurs. The DSMB may terminate 
the study earlier based on safety concerns.  

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 6 of 52 
# 
Criteria for 
Evaluation 
Primary efficacy endpoint: 
1. Relapse free survival 
 
Secondary efficacy endpoints: 
1. Melanoma subtype, as assessed clinically and histologically 
2. Melanoma site, as clinically recorded  
3. 25(OH)D3 serum levels at diagnosis and at 6 months 
intervals 
4. Stage of melanoma patient at diagnosis according to the 
2009 AJCC Melanoma staging and classification 
 
Safety endpoints: 
• 
Incidence and severity of adverse events 
Sample size 
Approximately 500 patients. 
 
Version and date of 
final protocol 
First version, 10-10-2012 
Version and date of 
protocol 
amendments 
Second version, 22-03-2013 
Third version, 20-08-2013 
Fourth version, 25-11-2015 
Fifth version, 27-09-2017 
Sixth version, 20-02-2018 
Seventh version, 19-03-2019 
Eight version, 05-01-2021 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 7 of 52 
# 
 
Statistical methods The analysis of efficacy and safety will be performed for an 
intention-to-treat (ITT) population, defined as all randomized 
patients. No interim analysis for efficacy is foreseen. 
. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 8 of 52 
# 
 
Signatures 
This study protocol was subjected to critical review. The information it contains is consistent with the current risk/benefit 
evaluation of the investigational medicinal product as well as with the ethical and scientific principles governing clinical 
research as set out in the Declaration of Helsinki and the guidelines on Good Clinical Practice. 
This protocol is approved by: 
 
 
 
 
 
 
 
 
 
 
 
 
Coordinating 
Investigator: 
 
 
 
 
 
 
Date 
 
Prof. Marjan Garmyn 
 
 
 
 
 
 
Statistician: 
 
 
 
 
 
 
Date 
 
Dr. Kris Bogaerts 
 
 
 
 
 
 
Signatory 3  
as applicable 
 
 
 
 
 
 
Date 
 
Name 
 
 
 
 
 
Signatory 4  
as applicable 
 
 
 
 
 
 
Date 
 
Name 
 
 
 
 
 
 
 
 
 
 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 9 of 52 
# 
Declaration of Investigator 
I have read this study protocol and agree that it contains all the information required to conduct the study. I agree to 
conduct the study as set out in this protocol. In particular, I agree to adhere to the ethical and scientific principles 
governing clinical research as set out in the Declaration of Helsinki and the Guidelines on Good Clinical Practice. 
Responsible Investigator at the Local Study Centre: 
 
 
Institution 
 
 
City 
 
 
 
Country 
 
 
 
 
Date  
 
 
Printed Name 
 
Signature 
 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 10 of 52 
# 
 
List of Study Core Facilities / Personnel 
 
Sponsor 
 
UZ Leuven 
Herestraat 40 
B-3000 Leuven 
 
 
 
 
Coordinating Investigator 
 
 
 
 
 
Subinvestigator 
 
 
 
 
 
 
 
Subinvestigator 
 
 
 
 
 
 
 
Subinvestigator 
 
Prof. Marjan Garmyn 
Head of Dermatology Department 
UZ Leuven 
Herestraat 49 
B-3000 Leuven 
 
Dr Eva Remenyik 
Dep of Dermatology 
Medical and Health Science Center 
University of Debrecen 
H-4012 Debrecen 
Nagyerdei krt 98 
Hungary 
 
Dr Tine Strobbe 
Dermatology 
Universitair Ziekenhuis Antwerpen 
Wilrijkstraat 10 
2650 Edegem 
Belgium 
 
 
Dr Arjen Nikkels 
Dermatology 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 11 of 52 
# 
Centre Hospitalier Universitaire de Liège 
Domaine du Sart Tilman 
Bâtiment B35 
B-4000 Liege  
Belgium 
 
 
 
 
Central Serious Adverse 
Event Processing Centre 
 
Leuven Coordinating Centre 
U.Z. Gasthuisberg 
Herestraat 49 bus 7003 
B-3000 Leuven 
 
 
 
Interactive Voice Response 
System Centre 
 
Leuven Coordinating Centre 
U.Z. Gasthuisberg 
Herestraat 49 bus 7003 
B3000 Leuven 
 
 
 
 
Laboratory 
 
 
Laboratoriumgeneeskunde (LAG) 
Herestraat 49 
B- 3000 Leuven 
 
 
Analysis of SNPS 
 
 
Laboratorium voor Translationele Genetica (VIB-KULeuven) 
 
 
 
 
 
ON IV  
 
 
 
 
 
 
Herestraat 49_ bus 912 
 
 
 
 
 
B-3000 Leuven 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 12 of 52 
# 
 
Table of Contents 
 
PROTOCOL SYNOPSIS ......................................................................................................................................................... 2 
Signatures ............................................................................................................................................................................ 8 
Declaration of Investigator ................................................................................................................................................... 9 
List of Study Core Facilities / Personnel ............................................................................................................................. 10 
List of Abbreviations ........................................................................................................................................................... 15 
1. 
INTRODUCTION ....................................................................................................................................................... 17 
1.1. 
Background ........................................................................................................................................................... 17 
1.2. 
Rationale of the study ............................................................................................................................................ 21 
1.3. 
Risk-benefit assessment ........................................................................................................................................ 22 
2. 
STUDY OBJECTIVES ................................................................................................................................................ 24 
2.1. 
Primary objective ................................................................................................................................................... 24 
2.2. 
Secondary objective ............................................................................................................................................... 24 
3. 
OVERALL DESIGN AND PLAN OF THE STUDY ......................................................................................................... 25 
3.1. 
Overview of study flow ........................................................................................................................................... 25 
Figure 1: Study Flow Chart .......................................................................................................................................... 26 
3.2. 
Justification of study design .................................................................................................................................. 27 
3.3. 
Study population ................................................................................................................................................... 27 
3.3.1. 
Number of patients ......................................................................................................................................... 27 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 13 of 52 
# 
3.3.2. 
Inclusion criteria ............................................................................................................................................. 28 
3.3.3. 
Exclusion criteria ............................................................................................................................................ 28 
4. 
STUDY CONDUCT .................................................................................................................................................... 29 
4.1. 
Schedule of procedures ......................................................................................................................................... 29 
Table 1: Schedule of assessments ................................................................................................................................ 29 
4.2. 
Patient screening and randomization ..................................................................................................................... 30 
4.3. 
Description of study assessments .......................................................................................................................... 31 
4.3.1. 
Medical history / demographics ...................................................................................................................... 31 
4.3.2. 
Staging of melanoma ....................................................................................................................................... 31 
4.3.3. 
Follow-up for relapse ....................................................................................................................................... 32 
4.3.4. 
Clinical laboratory ........................................................................................................................................... 32 
4.3.5. 
Concomitant medications ................................................................................................................................ 33 
4.3.6. 
Safety .............................................................................................................................................................. 33 
4.3.7. 
Data Safety Monitoring Board (DSMB) ............................................................................................................ 34 
4.3.8. 
Study duration for study patients ................................................................................................................... 35 
4.3.9. 
Duration of the whole study ............................................................................................................................ 35 
5. 
INVESTIGATIONAL MEDICINAL PRODUCT .............................................................................................................. 35 
5.1. 
D-Cure® (cholecalciferol) ....................................................................................................................................... 35 
5.1.1. 
General information ........................................................................................................................................ 35 
5.1.2. 
Labelling ......................................................................................................................................................... 37 
5.1.3 Storage ............................................................................................................................................................... 37 
5.1.4 Transfer .............................................................................................................................................................. 37 
5.1.5. Use, accountability and destruction ................................................................................................................... 37 
5.2. 
Olive oil ................................................................................................................................................................. 38 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 14 of 52 
# 
5.2.1. 
General information ........................................................................................................................................ 38 
5.2.2. 
Labelling ......................................................................................................................................................... 39 
5.2.3. 
Storage ............................................................................................................................................................ 39 
5.2.4. 
Transfer .......................................................................................................................................................... 39 
5.2.5 Use, accountability and destruction .................................................................................................................... 39 
6. 
ADVERSE EVENTS AND CLINICAL EVENTS ............................................................................................................ 39 
6.1. 
Definitions ............................................................................................................................................................. 39 
6.1.1. 
Adverse event .................................................................................................................................................. 39 
6.1.2. 
Serious and non-serious adverse events .......................................................................................................... 40 
6.1.3. 
Severity assessment ........................................................................................................................................ 41 
6.1.4. 
Causality assessment ...................................................................................................................................... 41 
6.2. 
Clinical handling ................................................................................................................................................... 41 
6.3. 
Collection period .................................................................................................................................................... 42 
6.4. 
Documentation and reporting ................................................................................................................................ 42 
6.4.1. 
Documentation of SAEs .................................................................................................................................. 42 
6.4.2. 
Documentation and reporting of SAEs ............................................................................................................ 42 
6.4.3. 
Reporting of serious adverse events to competent authorities and concerned ethics committees ..................... 43 
6.4.4. 
Documentation of abnormal laboratory values ................................................................................................ 43 
6.4.5. 
Documentation and reporting of IMP exposure during pregnancy or lactation ................................................. 44 
7. 
STATISTICAL METHODS .......................................................................................................................................... 44 
7.1. 
Sample Size ........................................................................................................................................................... 44 
7.2. 
Statistical Methods ................................................................................................................................................ 44 
8. 
ETHICAL, ADMINISTRATIVE AND LEGAL ASPECTS ................................................................................................. 45 
8.1. 
Ethical conduct of the study and informed consent ............................................................................................... 45 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 15 of 52 
# 
8.2. 
Study-specific committees ..................................................................................................................................... 46 
8.2.1. 
Study Executive Committee............................................................................................................................. 46 
8.2.2. 
Data & Safety Monitoring Board ...................................................................................................................... 46 
8.2.3. 
Clinical endpoint committee ............................................................................................................................ 47 
8.3. 
Case report forms .................................................................................................................................................. 47 
8.4. 
Quality control ...................................................................................................................................................... 47 
8.4.1. 
Study monitoring and inspections ................................................................................................................... 47 
8.5. 
Confidentiality ....................................................................................................................................................... 47 
8.6. 
Use of records and archiving ................................................................................................................................. 47 
8.6.1. 
Publication and use of study findings .............................................................................................................. 47 
8.6.2. 
Archiving of study records ............................................................................................................................... 48 
8.7. 
Insurance/Indemnity ............................................................................................................................................ 48 
8.8. 
Financial Aspects .................................................................................................................................................. 48 
9. 
REFERENCES .......................................................................................................................................................... 48 
 
List of Abbreviations 
7-DHC 
7 Dehydrocholesterol 
AE 
 
adverse event 
AJCC  
American Joint Committee of Cancer 
ALM  
Acrolentigonous malignant melanoma 
BCC  
Basal cell carcinoma 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 16 of 52 
# 
CE 
 
clinical event 
CEC  
clinical event committee 
CMM  
Cutaneous malignant melanoma 
DSMB  
data and safety monitoring board 
eCRF  
electronic case report form 
GCP  
good clinical practice 
GMP  
good manufacturing practice 
IMP 
 
investigational medicinal product 
IVRS  
interactive voice response system 
LMM  
Lentigo Malignant Melanoma 
NMM  
nodular malignant melanoma 
SAE 
 
serious adverse event 
SCC 
 
Squamous cell carcinoma 
SSMM  
superficial spreading malignant melanoma 
SUSAR 
suspected unexpected serious adverse reaction 
VDR  
Vitamin D Receptor 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 17 of 52 
# 
 
1. INTRODUCTION 
1.1. 
Background 
Cutaneous malignant melanoma (CMM) is the most common lethal skin disease, affecting mainly Caucasians worldwide 
and currently in Flanders the 10th most frequent tumor in males and 5th most frequent tumor in females (Belgian Cancer 
Registry 2008). Although CMM only accounts for 4 % of all malignant tumors of the skin, it is responsible for 80% of the 
skin cancer related deaths (Miller, 2006; Jemal, 2008). Incidence rates of this disease have been escalating in the last 
decades and it is forecasted that the incidence will further exacerbate the coming years (Garbe, 2009). In Belgium, a steady 
rise in the incidence of cutaneous melanoma has been reported as well (Belgian Cancer Registry, 2008). CMM arises from 
transformed melanocytes in the skin. These melanocytes are situated in the basal layer of the epidermis. Melanomagenesis 
implicates a stepwise transformation of melanocytes to melanoma, all or not with intermediate steps comprising ordinary 
and dysplastic naevi, and subsequent superficial and deep invasion, and metastasis (Miller, 2006). Several risk factors 
have been linked to the development of malignant melanoma.  The strongest risk factors for melanoma are a family history 
of melanoma (two or more cases of melanoma in first degree relatives), multiple benign (more than 100) or atypical naevi, 
and a previous melanoma. Immunosuppression, low phototype (characterized by having a fair skin, poor ability to tan or 
freckled complexion with or without red hair), and exposure to ultraviolet light (especially short bursts of acute exposure in 
childhood and severe sunburn) are additional risk factors (Bataille, 2008). Each of these risk factors corresponds to a 
genetic predisposition or an environmental stressor, which contributes to the genesis of melanoma.  At least some of these 
factors are understood to various degrees at the molecular level. For example 25 to 40 percent of the members of 
melanoma-prone families have mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A). Polymorphisms in the 
melanocortin 1 receptor (MC1R) have been linked to fair skin and red hair and have been associated with increased risk of 
melanoma (Miller 2006). Single nucleotide polymorphisms at 9p21 and 22q13 involved in cutaneous nevi development 
(Falchi, 2009) have also been associated with increased melanoma risk (Bishop 2009). 
The most important clinicopathological subtypes of melanoma are superficial spreading malignant melanoma (SSMM), 
nodular malignant melanoma (NMM), lentigo malignant melanoma (LMM), and acrolentiginous malignant melanoma 
(ALMM). SSMM is the most frequent subtype within the Caucasian population. Diagnostic signs are progressive 
asymmetrical enlargement of a pigment lesion which also demonstrates irregularity in colour and irregularity in shape.   

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 18 of 52 
# 
NMM are less frequent, occur mostly in males and are the most aggressive form, since they show a vertical growth phase 
from the beginning. They present themselves as rapid growing black often ulcerated tumors. LMM arises in a long standing 
pigmented precursor lesion and is located on chronic photodamaged skin. ALMM appear on palms and soles initially as flat 
pigmented lesions resembling moles, which start to increase in size and ultimately develop irregular areas of pigmentation. 
Subungual melanomas are most often located on the thumb nail of the great toe and present themselves as a narrow 
pigmented band, which slowly widens and ultimately produces a subungual mass. Different risk factors are associated 
with different subtypes of CMM and different locations of malignant melanoma: while chronic photodamage preferentially 
associates with LMM and malignant melanoma on head and neck region, a high count of naevi preferentially associates 
with malignant melanoma on the trunk, indicating that different pathways may lead to the development of malignant 
melanoma, i.e. a pathway through chronic sun exposure, and a melanomagenetic pathway (Whiteman, 2003). Different 
subtypes of malignant melanomas show also a significant genetic heterogeneity: CMM arising in sites intermittently 
exposed to the sun harbor BRAF and/or N-ras mutations more frequently; while malignant melanomas on chronically sun 
exposed skin (LMM) and ALM show more frequent c-Kit mutations (Curtin 2006). While cutaneous malignant melanoma, 
when diagnosed and treated in an early stage (pure radial or early invasive growth phase) has a very good prognosis and 
can still be treated in a curative way via surgery, metastatic melanoma decreases the chances of survival markedly, 
because of the inherent resistance of the melanoma cells to classical cytotoxic chemotherapy.  The most important 
predictor of progression of malignant melanoma and survival is Breslow thickness of the primary tumor at diagnosis. 
Breslow thickness is a histological characteristic of the tumor and refers to the thickness of the tumor, measured as the 
distance between the granular layer of the epidermis and the deepest tumor cell in millimetres. According to the recent 
final version of the 2009 American Joint Committee of Cancer (AJCC) melanoma staging and classification, primary tumor 
ulceration and primary tumor mitotic rate are considered as independent prognostic factors for survival and have been 
included in tumor staging (Balch 2009). For instance, patients with a melanoma equal or less than 1 mm thickness, 
without ulceration or mitosis and without nodal or distant metastasis (T1aN0M0, stage IA) have a very good prognosis, 
reflected by a five and ten year survival of respectively 97 and 93%, whereas patients with an ulcerated melanoma of over 4 
mm thickness, but without nodal or distant metastasis at diagnosis (T4bN0M0) have a 5 and 10 year survival of 53% and 
39% respectively. Once distant metastasis occurs, the prognosis is bad, i.e. a patient with distant metastatic melanoma to 
the viscera (stage IV, M1c) has a 1 year survival of 33% (Balch 2009). Other known predictive prognostic factors are 
presence and distribution of tumor infiltrating lymphocytes, tumor site, sex, and social deprivation. (Balch, 2009; Newton 
Bishop 2009). 
 
 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 19 of 52 
# 
Vitamin D status: current knowledge 
There are 3 sources of vitamin D: endogenous production in skin upon absorption of ultraviolet (UV) B (290-315 nm) 
radiation, vitamin D in foods and finally dietary supplements. Since a standard western diet contains only very few food 
components, which contain vitamin D (fatty fish and liver extracts) our  most important source of vitamin D  is endogenous 
conversion of 7-dehydrocholesterol (7-DHC) to previtamin D3 by UVB,  which isomerizes to vitamin D3 by thermal energy. 
However, this vitamin D synthesis is only reliably available year-round at latitudes between 40 ° north and 40 ° south, 
indicating that in our regions the required levels of UVB are low or non-existent for a significant proportion of the year. 
Data indicate that indeed insufficient vitamin D levels are widespread both in the American and European population 
(Holick 2006; Lee 2009; Adams 2010,) especially in wintertime (Rhodes 2010). 
Vitamin D (from the food, via supplements or produced by UVB in the skin) is biologically inert and the biological effect of 
vitamin D results only as a consequence of its sequential metabolisation in the liver into 25-hydroxy-vitamin D3 
(25(OH)D3) and then in the kidney into the steroid hormone, 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3). The classical 
signaling pathway of 1,25(OH)2D3 employs the vitamin D receptor (VDR), which is a transcription factor for 1,25(OH)2D3 
target genes, including the cyclin dependent kinase inhibitors, p21 and p27. 
Vitamin D receptor (VDR) is believed to be located in the nucleus prior to activation by 25(OH)2D3, which dissociates from 
the serum vitamin D-binding protein, enters the cell by diffusion and binds the VDR. Ligand binding produces 
conformational changes, resulting in dimerization, necessary for high affinity interaction with target gene promoter at the 
vitamin D response element (Osborne, 2002). 
The gene encoding VDR maps to the chromosomal region 12q13 and contains numerous common variants, that are 
hypothesized to influence the function and or expression of VDR (Egan 2009). 
It is generally agreed that the serum concentration of 25(OH)D3 in normal subjects is the  best indicator for vitamin D 
status and currently a serum concentration below 10 ng/ml (<25/ nmol/L) is considered as vitamin D deficient, and a 
serum concentration below 20 ng/ml (< 50 nmol/L) as vitamin D insufficient. The optimal level for health is believed to be 
reached at 30 ng/ml (75 nmol/L), while some individuals may be at risk for toxicity (hypercalcaemia, vomiting thirst, 
polyuria, ectopic calcifications) when their 25(OH)D3 levels are in the range of 100-150 ng/ml (or 250-300 nmol/L). 
Current recommendation for additional vitamin D intake via supplements, in addition to skin synthesis and nutritional 
intake is 1000 IU/d. A good safety profile for this amount has been shown in more than 50 000 subjects over a several 
year treatment period (Norman and Bouillon, 2010), while doses for chemoprevention studies (colon, prostate and breast 
cancer) range from 2000 to 4000 IU /day (ClinicalTrials.gov). A recent IWT/TBM project investigating the effect of vitamin 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 20 of 52 
# 
D supplementation on Chronic Obstructive Pulmonary Disease (COPD) on 90 patients in a placebo controlled setting, has 
shown that a single monthly dose of 100 000 IU, given during a year is safe, is able to increase the 25 (OH)D3 levels in 
serum, from insufficient levels (<20 ng/ml) to 50 ng/ml(Lehouck, 2012). , and has no immunosuppressive effects (personal 
communication, Prof Wim Janssens and Prof Chantal Mathieu, UZ KULeuven). 
Another important finding is that vitamin D levels are influenced by the genetic variability of every individual.  Data from a 
very recent genome wide association study (Wang 2010) show that the following genes contribute to the variability of serum 
concentrations of 25(OH)D3: 7-DHC reductase (responsible for the availability of 7-DHC in the skin), the liver 25-
hydroxylase CYP2R1 (involved in the conversion of vitamin D into 25-hydroxyvitamin D3) and CYP24A1 (key degradation 
enzyme). Additionally polymorphisms in GC, the gene encoding vitamin D-binding protein, had the greatest effect on serum 
25-hydroxyvitamin D3 concentration. 
Vitamin D and melanoma: current knowledge. 
Laboratory data, animal studies, epidemiological observations and clinical studies indicate that Vitamin D may have a 
preventive effect on melanoma development and may affect tumor progression or melanoma outcome 
The VDR has been identified in cultured melanoma cells, in melanoma xenografts and in primary melanoma tissue 
(reviewed by Osborne 2002 and Egan 2009). Vitamin D metabolites have been shown to inhibit proliferation and induce 
differentiation in melanoma cell lines. In vivo 1,25 (OH)2 D3 has been shown to suppress growth in human melanoma 
derived xenografts in immunosuppressed mice. Pretreatment of mouse melanoma cells with 1,25(OH)2D3 resulted in 
inhibition of migration through extracellular matrix and adherence of the cells to reconstituted basement membrane 
(Matrigel) type IV collagen and inhibition of the formation of lung metastases, indicating an inhibitory effect on tumor 
invasion and metastasis. 
Skin is an important target site for the actions of vitamin D. Photochemical reactions that produce pre Vitamin D3 
(cholecalciferol) only take place in the skin. Keratinocytes and other cells in the skin are capable of synthesizing 
hormonally active vitamin D metabolite, 1,25(OH)2D3 and there is evidence that 1,25(OH)2D3 can protect skin cells from 
UV damage (De Haes 2005; Gupta 2007). 
Epidemiological evidence for a possible protective influence of sunlight/vitamin D on melanoma risk is suggested by 
studies showing lower than expected incidence in persons with outdoor occupations, which, according to the authors, 
could reflect at least in part a level of protection afforded by their greater reserves of vitamin D.  The majority of melanomas 
occur at body sites only receiving intermittent sun exposure, consistent with possibility of inadequate production of 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 21 of 52 
# 
vitamin D as possible cofactor in sites with limited exposure to sun, like trunk and extremities. FokI and BsmI 
polymorphisms in the VDR, which may influence expression or activity of this protein are associated with an altered 
melanoma risk (Gandini, 2009). However large epidemiological studies have failed to find an association between dietary 
vitamin D intake and melanoma incidence (Weinstock 1992; Asgari 2009) and between serum vitamin D levels and 
melanoma risk (Randerson-Moor 2009). 
Added value compared to current knowledge/state of the art initiatives 
Vitamin D levels may have a protective effect on malignant melanoma outcome, as suggested by a reported association of 
higher 25(OH)D3 serum levels at diagnosis with lower Breslow thickness at diagnosis. Increased 25(OH)D3 serum levels at 
diagnosis were also independently protective of relapse and death (Newton Bishop, 2009). In the present proposal, we 
expand these investigations on the potential protective effect of vitamin D on melanoma outcome in a more comprehensive 
way, because of the following reasons: 
1. We will test the protective effect of vitamin D supplementation to melanoma patients (in a placebo controlled and double 
blind way) against relapse (primary endpoint). 
2. We will also immunohistochemically assess the expression of the Vitamin D Receptor (VDR) expression in the primary 
tumor, and investigate whether VDR immunoreactivity in the primary tumor correlates with relapse (primary endpoint)  
and melanoma stage at diagnosis. (secondary endpoint) 
3. We will monitor increases in vitamin D levels after supplementation (secondary endpoint). This will allow us to assess 
whether every patient is characterized by the same increase in vitamin D, or whether serum levels following intake depends 
on genetic variability. Furthermore, this will allow us to monitor compliance to the supplementation.  
4. We will correlate vitamin D levels at diagnosis with melanoma site (secondary endpoint) and subtype (secondary 
endpoint). 
1.2. 
Rationale of the study 
The rationale for this project is the need to improve the outcome of malignant melanoma of the skin, the most 
common lethal skin disease, with a large impact in terms of years of life lost. While early stage malignant melanoma (pure 
radial, early invasive growth phase) can be cured, late stage (metastatic) melanoma decreases the chances of survival 
markedly because of its resistance to chemotherapy (Balch 2009). Predictors of melanoma progression and survival include 
histological characteristics of the primary tumor at diagnosis: Breslow thickness, presence of ulceration and number of 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 22 of 52 
# 
mitoses. Improvement of melanoma outcome can be achieved by diagnosing the tumor in an earlier stage (thinner Breslow, 
absence of mitosis and absence of ulceration) and by decreasing the chance of relapse after surgery of the tumour. 
We hypothesize that high dose vitamin D supplementation after surgery of the primary tumor can decrease the chance of 
relapse, based on previous in vitro and vivo data, which support an anticancer effect of vitamin D. 
The active metabolite of vitamin D, 1,25(OH)2D3, demonstrates relevant anti-cancer effects on melanoma cells, not only 
antiproliferative, prodifferentiating and proapoptotic effects, but also inhibitory effects on tumor invasion and metastasis 
(Osborne, 2002 and Egan, 2009). These pleiotropic anticancer effects are mediated by the vitamin D receptor (VDR). 
Patients in stage IV (metastatic malignant) melanoma show reduced 25(OH)D3 serum levels and a recent study revealed an 
association of higher 25(OH)D3 serum levels with lower Breslow thickness of the tumor at diagnosis. (2009, Nürnberg, 
2009, Newton Bishop 2009) 
Serum concentration of 25(OH)D3 is the best indicator of the vitamin D status, which is determined by UVB induced 
production of vitamin D in the skin, dietary intake and vitamin D supplementation (Sage, 2010). In addition vitamin D 
status may also be influenced by genetic variants of certain proteins involved in the vitamin D pathway (Wang 2010). 
The proposed project will assess whether high dose vitamin D supplementation after surgery of the primary tumor 
affects malignant melanoma outcome. More specifically the following questions will be addressed: 
1. Is vitamin D supplementation after diagnosis and surgery of the primary tumor protective against a relapse of 
malignant melanoma? 
2. Does this protective effect on relapse correlate with VDR immunoreactivity in the primary tumor? 
1.3. 
Risk-benefit assessment 
In every clinical trial, anticipated benefits need to be weighed against the study associated risks.  It is generally agreed that 
the serum concentration of 25(OH)D3 in normal subjects is the best indicator for vitamin D status and currently a serum 
concentration below 10 ng/ml (<25/ nmol/L) is considered as vitamin D deficient, and a serum concentration below 20 
ng/ml (< 50 nmol/L) as vitamin D insufficient. The optimal level for health is believed to be reached at 30 ng/ml (75 
nmol/L), while some individuals may be at risk for toxicity (hypercalcaemia, vomiting, thirst, polyuria, ectopic 
calcifications) when their 25(OH)D3 levels are in the range of 100-150 ng/ml (or 250-300 nmol/L). Current 
recommendation for additional vitamin D intake via supplements, in addition to skin synthesis and nutritional intake, is 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 23 of 52 
# 
1000 IU/ d. A good safety profile for this amount has been shown in more than 50 000 subjects over a several year 
treatment period (Norman and Bouillon, 2010), while doses for chemoprevention studies (colon, prostate and breast 
cancer) range from 2000 to 4000 IU /day (ClinicalTrials.gov). A recent publication (Lehouck et al, 2012) investigating the 
effect of vitamin D supplementation on Chronic Obstructive Pulmonary Disease (COPD) on 90 patients in a placebo 
controlled setting, has shown that a single monthly dose of 100 000 IU, given during a year is safe, is able to increase the 
25 (OH)D3 levels in serum, from insufficient levels (<20 ng/ml) to 50 ng/ml, and has no immunosuppressive effects. 
The anticipated benefits high dose vitamin D supplementation for study participants are expected better long-term 
outcomes such as reduced occurrence of relapse and longer relapse free survival period. Given the increased mortality of 
melanoma patients that progress to a higher stage (Balch et al, 2009) and the patients’ burden that is associated with this 
course (including intensive medical treatment, financial impact and/or inability to work), the ViDMe study offers a valuable 
adjuvant, low invasive treatment opportunity for participating patients. In view of these facts, the risk benefit ratio seems 
well balanced in the ViDMe trial so that the benefits outweigh the risks. To account for the described risks, the ViDMe 
study will assess complications/adverse events associated with vitamin D supplementation. A DSMB Committee will 
analyze key safety aspects in regular intervals during the ongoing trial to ensure patient safety. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 24 of 52 
# 
 
2. STUDY OBJECTIVES 
2.1. 
Primary objective 
The primary endpoint for this study is  
• 
Relapse free survival. 
2.2. 
Secondary objective 
Secondary efficacy endpoints are: 
• 
Melanoma subtype, as assessed clinically and histologically 
• 
Melanoma site, as clinically recorded  
• 
25(OH)D3 serum levels at diagnosis and at 6 months intervals 
• 
Stage of melanoma patient at diagnosis according to the 2009 AJCC Melanoma staging and classification 
 
Safety endpoints: 
• 
Incidence and severity of adverse events 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 25 of 52 
# 
 
3. OVERALL DESIGN AND PLAN OF THE STUDY 
3.1. 
Overview of study flow 
To investigate whether vitamin D supplementation after diagnosis affects malignant melanoma outcome (primary endpoint 
relapse free survival), stage IB-III patients will be enrolled from fall 2012 to fall 2023. Stage IA patients will not be included 
in the study because they only have a very small chance to relapse. This double-blind randomized study will comprise 500 
patients (stage IB-III). This patient cohort will be randomized in a 1:1 ratio to vitamin D supplementation or placebo. We 
will also assess the expression of the Vitamin D Receptor (VDR) expression in the primary tumor. A blood sample will be 
taken for DNA analysis (genetic variability in the vitamin D pathway). We will check 25(OH)D3 serum levels both at 
diagnosis, and every 6 months until the end of the study.  This patient cohort will exist of 3 subgroups (patients diagnosed 
within 6 or 12 months before start of the study and newly diagnosed patients). Inclusion of previously diagnosed patients 
will allow us to assess whether delayed supplementation has a similar effect on the relapse free survival rate as immediate 
supplementation after surgery of the tumor. 
In this randomized vitamin D supplemented placebo-controlled trial (both arms), we will assess whether vitamin D 
supplementation in the follow up period after diagnosis has a protective effect on relapse (primary endpoint) of the 
malignant melanoma and whether this protective effect correlates with the vitamin D receptor immunoreactivity in the 
primary tumor. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 26 of 52 
# 
 
Figure 1: Study Flow Chart 
 
. 
 
 
Patients with diagnosed with histologically proven malignant 
melanoma (IB-III), will be assessed for eligibility 
Randomly assigned (n=500) 
Will be assigned to receive placebo 
(n=250)  
Will be assigned to receive Vitamin D 
(n=250) 
Site visit follow up every 3 months 
End of study or relapse 
Site visit follow up every 3 months 
End of the study or relapse  

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 27 of 52 
# 
 
3.2. 
Justification of study design  
A previous study has demonstrated the association of higher 25-hydroxyvitamin D3 serum levels with lower Breslow 
thickness of the tumor at diagnosis (Newton-Bishop, 2009), suggesting a protective effect of higher vitamin D levels on 
disease progression of cutaneous malignant melanoma. 
To further proof the protective effect of Vitamin D supplementation on melanoma disease progression, this study will give 
high dose vitamin D supplementation to the melanoma patients after surgery of the primary tumor ( which is the current 
best standard of care), in a placebo controlled and double blind way. The effect of high dose vitamin D supplementation in 
double blind placebo controlled way will be primarily tested on relapse free survival. 
Patients will be randomly assigned in a 1:1 ratio to receive a monthly oral dose of 100 000 IU of vitamin D (1ml of D-Cure) 
or placebo (1 ml of olive oil). A block randomization method stratified on time of diagnosis (newly diagnosed, 0-6 months or 
6-12 months before start of the study) will be used to overcome seasonal influences on baseline characteristics. 
We will also assess the expression of the Vitamin D Receptor (VDR) expression in the primary tumor. A blood sample will 
be taken for DNA analysis (genetic variability in the vitamin D pathway). We will check 25(OH)D3 serum levels both at 
diagnosis, and every 6 months until the end of the study. If the level of 25(OH)D3 serum is above 80 ng/ml, study drug will 
be interrupted and during drug free interval the 25(OH)D3 serum levels will checked every 3 months. When serum 25 
(OH)D3 falls below 50 ng/ml, study drug is restarted  
The patient cohort will exist of 3 subgroups (patients diagnosed within 6 or 12 months before start of the study and newly 
diagnosed patients). Inclusion of previously diagnosed patients will allow us to assess whether delayed supplementation 
has a similar effect on the relapse free survival rate as immediate supplementation after surgery of the tumor.  
3.3. 
Study population 
3.3.1. Number of patients 
A total of approximately 500 male and female patients will be enrolled in the ViDMe study in this multiple centre study.  

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 28 of 52 
# 
 
3.3.2. Inclusion criteria 
1. 
Older than 18 years and younger than 80 years of age. 
2. 
Histologically proven malignant melanoma, stage IB to III Not participating in other clinical trial. 
3. 
The only treatment for melanoma is surgical treatment. 
4. 
Complete resection of melanoma. 
5. 
Single primary invasive cutaneous melanoma (inclusion within 1 year after diagnosis). 
6. 
Signed ethical committee approved informed consent 
7. 
Serum phosphate and calcium at the entry of the study within normal range of the laboratory reference 
3.3.3. Exclusion criteria 
1. 
Pregnant/lactating women or planning on becoming pregnant during the study  
2. 
Known hypersensitivity to vitamin D or its components. 
3. 
Pre-existing renal stone disease or chronic renal disease 
4. 
With eGRF < 30 mL/min/1.73 m2 or renal dialysis. 
5. 
Liver failure or chronic liver disease with liver enzyme > 2 fold ULN (=upper limit of normal) 
6. 
History of parathyroid disease or granulomatous disease (TBC and sarcoidosis) 
7. 
History of malabsorption syndrome or any medical condition that might interfere with vitamin D absorption. 
8. 
History of other malignancy  within the last 5 years except for carcinoma in situ of the cervix or basal cell carcinoma 
or squamous cell carcinoma of the skin or in situ malignant melanoma. 
9. 
Chronic alcohol abuse. 
10. 
Medical or logistic problems likely to preclude completion of the study. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 29 of 52 
# 
 
4.  STUDY CONDUCT 
4.1. 
Schedule of procedures 
The schedule of study assessment is listed in Table 1. 
Table 1: Schedule of assessments 
 
Screening 
 
Randomization 
= day 0 
Every 3 months 
FU 
Every 6 months 
FU 
 
End of Study (fall 2023) or 
Progression/Relapse 
Informed Consent 
X 
 
 
 
 
Demographics 
X 
 
 
 
 
Medical History 
X 
 
 
 
 
Melanoma Risk Factors 
X 
 
 
 
 
Sun exposure Behaviour 
X 
 
 
 
X 
 
 
Physical Examination 
X 
 
x 
 
X 
 
Vitamin D levels 
 
X 
 
X 
X 
DNA analysis 
 
x 
 
 
 
Safety Laboratory# 
X 
 
X 
x 
X 
Concomitant Medications 
X 
X 
X 
 
X 
Adverse Event / 
Endpoint Collection 
 
X 
X 
 
X 
24 hour urine calcium 
 
 
 
 
X 
 
+  

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 30 of 52 
# 
# Safety laboratory 
 
Screening and end of study:  
Hemoglobin, haematocrit, WBC count with differential, RBC count and platelet count 
Renal function (creatinine) 
Liver function (AF, ALT, gamma-GT, LDH)  
Serum calcium and serum phosphate, and albumin 
 
Every 3 months:  
serum calcium, serum phosphate, 
 
Every 6 months 
WBC count plus differential 
 
4.2. 
Patient screening and randomization 
Patients are recruited upon presentation and recruitment is based on the stage of 
melanoma. 
Stage IB-III patients will be enrolled from fall 2012 to fall 2023.  
After staging and surgical treatment, and after obtaining written informed consent, 
patient will undergo screening at the investigational site to ensure that the patient 
meets all other in- and exclusion criteria. Written informed consent must be obtained 
from patients prior to any study specific procedure (for details see section 8.1). After 
consenting patients undergo the procedures listed for the screening visit. If the patient 
meets all in- and exclusion criteria, the patient will then be randomized using a 
specifically designed Interactive Voice Response system (IVRS) on an equal basis (1:1) 
to either vitamin D or placebo stratified on time of diagnosis (newly diagnosed, 0-6 
months or 6-12 months before start of the study). The IVR system will supply a patient 
number that will be used as the key identifier for the entire study period. Patients in 
both arms will receive similar looking capsules, containing either 100 000 IE 
cholecalciferol or placebo oil. The randomization schedule will be kept under closure at 
the data management centre. All other study staff members, dermatologists, trail 
nurses, and patients will be blinded to the treatment allocation. The DSMB members 
may be unblinded to assess the safety of the patients. The study complies with the 
Helsinki declaration of medical research and needs approval by the hospital medical 
ethics committee. Written informed consent will be obtained prior to enrolment. 
In these stage IB-III melanoma patients (500 patients), we will take a blood sample for 
serum analysis (25(OH)D3 levels) at the moment of diagnosis and, every 6 months 
until relapse or until the end of the study. 
Every participant will also be asked to complete a questionnaire regarding melanoma 
risk factors, including amount and type of sun exposure and to undergo skin 
examination for the assessment of phototype, naevus phenotype and actinic damage. 
We will measure patient’s height and weight, which will be used to estimate body mass 
index (BMI). 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 31 of 52 
# 
Our power calculations are based on a patient enrolment rate of 500 melanoma 
patients until the end of the study. In order to meet those targets, a multicentre study 
is necessary, via participation of other academic centers.  
4.3. 
Description of study assessments 
4.3.1. Medical history / demographics 
A complete medical history is obtained from each patient at the screening visit. 
Demographics, including gender, age and country of birth of all four grandparents, and 
the smoking status are recorded. 
4.3.2. Staging of melanoma 
Patients are ranked according to the following staging system: 
Pathological staging of the primary tumor: is performed at the department of  
Pathology of the participating centers and is based on the Breslow thickness of the 
tumor, mitotic rate and presence or absence of ulceration. Breslow thickness of the 
tumor is measured by a calibrated eye piece graticule, and reflects the distance from 
the granular layer of the epidermis to the deepest tumor cell in millimetres. Mitotic rate 
is determined by the hot spot approach (as recommended by the melanoma Staging 
Committee) and expressed as the number of mitoses per square millimetre (i.e. 11 high 
power fields) of primary tumor. Presence or absence of ulceration is determined on 
Hematoxilin and Eosin sections. 
Staging for regional metastatic melanoma: is performed by routine physical 
examination, including palpation of the lymph nodes and ultrasound examination of 
the lymph node regions. Ultrasound of the drainage region with FNAC for cytological 
evaluation will be performed in patients with suspicious nodes by ultrasound. In case 
of lymph node metastasis PET-CT and brain MRI is performed to exclude general 
metastatic loci, and patients undergo a complete lymphadenectomy.  
Patients with negative nodes (clinically and by ultrasound) but with primary tumor 
pathology at intermediate or high risk for tumor metastasis (Breslow > 1 mm or 
≤ 1 mm but with ulceration and/ or mitosis ≥1/mm2), are candidate for lymphatic 
mapping with sentinel lymph node biopsy. When the sentinel node is positive these 
patients will have a PET-CT and brain MRI to exclude general metastatic loci, and 
undergo a complete lymphadenectomy.  
Nodal micrometastasis are detected by routine H&E staining, supplemented by 
immunohistochemistry with a cocktail of antibodies directed against Melan-A, 
tyrosinase and gp100 (HMB45). Processing of the sentinel node and reporting of the 
results will be done according to EORTC guidelines. Stage IB-III patients are eligible for 
the vitamin D supplementation study if the only treatment is surgery. (Mohr et al, 
2009). 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 32 of 52 
# 
4.3.3. Follow-up for relapse 
Patients are taught the process of self-examination; Follow-up intervals are three-
monthly. Since up to 70% of the first recurrence is found in the loco regional area, 
follow up visits will consist of routine physical examination, including full skin 
assessment and palpation of regional lymph nodes. Ultrasound of the lymph nodes will 
be performed in all patients at an interval of 6 months, or in case of palpable lymph 
nodes. Ultrasound of draining lymph nodes by experienced radiologists has higher 
sensitivity to detect relapse compared with clinical examination. (PET)CT to exclude 
distant metastasis and MRI to exclude brain metastasis will be performed in patients 
with new symptoms and physical findings. Routinely PET(CT) and MRI are not used in 
the follow up period, since there is lack of prospective studies proving the efficacy of 
these expensive imaging techniques in routine follow up. Since both arms in the study 
are followed identically, the primary endpoint of the study will not be hampered by this 
less invasive and aggressive follow-up approach. (Mohr et al, 2009) (Garbe et al, 2012). 
4.3.4. Clinical laboratory 
Blood sampling and sample analysis is performed at the clinical centre. The local 
investigator is responsible for proper judgment of abnormal blood test results, and is 
responsible to appropriate patient care following clinically relevant pathological results. 
Please refer to section 6.4.4 to determine whether an abnormal laboratory value may 
constitute an adverse event. 
The following analysis is to be obtained:  
Screening and end of study:  
▪ 
Hematology: hemoglobin, hematocrit, WBC count with differential, RBC count 
and platelet count 
▪ 
Biochemistry and enzymes: serum creatinine, serum calcium, serum phosphate, 
AF, ALT, gamma GT, LDH  
 
Randomisation (Day 0): 
▪ 
Baseline serum vitamin D level. 
▪ 
Bloodsample for DNA analysis 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 33 of 52 
# 
 
Every 3 months: 
▪ 
serum calcium 
▪ 
serum phosphorus 
▪ 
25(OH)D3 serum levels, in case of drug interruption when serum 25(OH)D3 
levels are > 80 ng/ml 
 
Every 6 months: 
▪ 
25(OH)D3 serum levels 
▪ 
WBC plus differential 
 
End of study: 24 hrs urine calcium 
 
SNP analysis will be performed by the laboratory of Professor Lambrechts, VIB 
Peripheral blood from study participants will be sampled in K2EDTA tubes. 
The samples are coded and only then transferred to VIB. So VIB only has coded 
information from the patients.  Subsequently, tubes will be transferred to the Vesalius 
Research Center (Leuven) and genomic DNA will be extracted by a standard salting out 
method and stored at -80 °C until further analysis. Genetic variants affecting VD levels 
will be genotyped in a blinded manner using iPLEX technology on a MALDI-TOF based 
MassARRAY Compact Analyser (Sequenom Inc., CA, USA). The Sequenom’s iPLEX 
technology efficiently multiplexes up to 32 different SNP’s in one PCR reaction, thereby 
providing rapid and accurate SNP genotypes at an affordable price. Only samples for 
which ≥ 80% SNPs have succeeded will be considered for further analysis. SNPs with a 
call rate < 98% will be re-designed and genotyped again to reach success rates close to 
100%. At least 5% of the samples will be genotyped in duplicate, to prove accuracy of 
the genotyping protocol. We expect that approximately 2 Sequenom assays will have to 
be applied on the DNA of participating individuals to cover all 19 SNPs. Multiple Single 
Nucleotide Polymorphisms (SNPs) have been reported to affect VD signaling.  
Following SNPs of the VDR will be determined: rs2228570 (Fok1), rs731236 (Taq1), 
rs1544410 (Bsm1), rs7975232 (Apa1), rs757343 (Tru91). Following 14 SNP’s of the VD 
pathway genes will be determined: rs12785878 (DHCR7 gene), rs10741657 (CYP2R1 
gene), rs59443548, rs1803361 rs2229381, rs11559242, rs41272685, rs41272687 (6 
SNP’s of CYP27A1 gene), rs10877012 (CYP27B1), rs2296241, rs2248359, rs6013897 
(CYP24A1), rs4588, rs7041 ( 2 SNPs for DPB gene). The SNP analysis will be in 
collaboration with the laboratory of Prof. Lambrechts.  
 
4.3.5. Concomitant medications 
All patients participating in the trial should receive treatment according to evidence-
based guidelines. Concomitant medications are recorded throughout the study. 
4.3.6. Safety 
-  serum calcium, phosphorus, to detect for vitamin D intoxication (every 3 months)  
- measurement of total WBC and differential (every 6 months) and a record of infection 
rate (every 3 months) to check for immunosuppressive effects  

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 34 of 52 
# 
Adverse clinical events 
All serious events will be reported to the Leuven coordinating Centre. See also section 
6.4. 
4.3.7. Data Safety Monitoring Board (DSMB) 
All safety parameters and adverse events will be reviewed by a DSMB. The DSMB is 
unblinded and composed of medical experts not involved in the study: a dermatologist, 
oncologist and statistician. They will assess the safety of patients based on the safety 
parameters and adverse events.  In particular, at regular intervals an unblinded 
interim analysis will be performed to assess the difference between the intervention 
arms and to exclude an increase in relapse rate in de vitamin D supplemented arm. No 
early stopping for efficacy will be allowed. Details of the DSMB responsibilities will be 
documented in a charter. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 35 of 52 
# 
 
4.3.8. Study duration for study patients 
Each enrolled patient will remain in the study throughout the entire study duration, 
with a maximum study follow-up of 3.5 years for each patient. A study patient’s 
participation may be terminated early because of relapse/progression which is the 
main study end point or due to a reasonable cause, such as the investigator’s medical 
decision. At any time, the patient has the right to withdraw consent without a negative 
impact on her/his medical treatment. 
4.3.9. Duration of the whole study 
Our power calculations are based on a patient enrolment rate of 500 melanoma 
patients during a recruitment phase of three years maximum. Concerning the 
enrolment period: the first patient will be recruited as a fall 2012 and the last patient 
in fall 2023. In orde to meet those targets, a multiple center study is necessary, via 
participation of other academic centers.  
The DSMB may terminate the study earlier based on safety concerns at any time. The 
sponsor may also terminate the study early for reasonable cause. Competent 
authorities/ethics committees retain the right for premature termination of the study 
according to applicable regulations. The study may also be terminated early if the work 
performed is not compliant with Good Clinical Practice. 
5. INVESTIGATIONAL MEDICINAL PRODUCT 
5.1. 
D-Cure® (cholecalciferol) 
5.1.1. General information 
• 
Name investigational product: D-Cure® (amp. cholecalciferol 100.000 U.I./ml) 
 
Content of 1 ml amp.: Cholecalciferol 100.000 U.I./ml -DL α-Tocopherol. acetas 
– 
           Sorbitol. oleic. polyoxyaethylenat. - Aetherol. aurantii corticis dulcis - olie van 
           olijfolie ad 1 ml 
 
 
• 
Administration route: orally 
• 
General properties: clear, (light) yellow oil 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 36 of 52 
# 
* D-Cure® amp. 100.000 U.I/ml  
           Licence number: BE436073 
           Licence holder: Laboratoires SMB NV, Herdersliedstraat 26-28, 1080 Brussel 
           Manufactured by SMB Technology S.A., 39 rue du Parc Industriel, Marche-en- 
           Famenne 
• 
Quality control tests for + specifications: 
           Since D-Cure® is a licenced drug, all quality control tests are performed by 
           Laboratoires SMB. 
 
For more information about D-Cure®: see the scientific package leaflet in 
attachment. 
*  
D-Cure® ampoules 100.000 U.I/ml are delivered in a blinded manner by 
Laboratoires SMB NV. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 37 of 52 
# 
 
 
5.1.2. Labelling 
• 
Local Pharmacy labels the D-Cure® ampoules 
• 
Example of label 
 
 
 
 
Protocol: ViDMestudy 
Investigator: of local academic center  
 
 
 
Vitamin D 100.000 IU vs placebo 
 
 
 
Pro  ampoules 
1ml 
 
 
 
Lot: …..  Expiration date: ……. 
 
 
 
Store at roomtemperature 
 
 
 
Exclusively for clinical research 
 
 
 
• 
 
5.1.3 Storage 
D-Cure® (oral ampoules) will be stored at room temperature, below 25 °C. Temperature 
(minimum and maximum temperature) is recorded electronically every working 
day. 
5.1.4 Transfer 
After release by a responsible person, the IMP’s can be transferred to the investigator, 
using a signed transfer document. IMP will not be transferred to another site. 
5.1.5. Use, accountability and destruction 
Pharmacists of the University Hospitals Leuven, who are independent from the clinical 
study team, will randomly assign participants by using a computer-generated 
randomization list and prepare the study medication. A diary will be given to the 
patient for dates when to take the medication (numbered syringes) on a monthly 
base, at a dose of 100 000 IU (1 ml of D-cure® suspension in ) or 1 ml of placebo 
(olive oil). Vitamin D and placebo are prepared by Laboratoires SMB NV in oral 
ampoules , identical in taste and appearance. Oral ampoules are numbered 
according the randomization schedule. At each visit 3 numbered ampoules are 
given to the patient, Patient will take empty ampoules  back to the control visit 
(every 3 months). Number of ampoules and date the Vitamin D/placebo is taken 
are registered. Subsequently empty ampoules are destroyed 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 38 of 52 
# 
5.2. 
Olive oil 
5.2.1. General information 
 
Name investigational product: Olive oil 
 
Olive oil will be used as matching placebo for vitamin D (cholecalciferol) 
Composition: Tocopherol Acetate, sweet orange peel oil, Polyglyceryl oleate, olive 
oil refined ad 1ml 
 
• 
Administration route: orally 
• 
General properties: clear, (light) yellow oil 
 
Olive oil 
            
• 
Quality control tests for + specifications: 
           Since Olive oil is manufactured by Laboratoires SMB and  all quality control 
tests are performed by Laboratoires SMB. 
 
 
 
Placebo ampoules are delivered in a blinded manner by Laboratoires SMB 
NV. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 39 of 52 
# 
 
5.2.2. Labelling 
Local pharmacy labels the placebo ampoules. 
Example of label 
 
 
 
 
Protocol: ViDMestudy 
Investigator: of local academic center 
 
 
 
Vitamin D 100.000 IU  vs placebo 
 
 
 
Pro  ampoule 
1ml 
 
 
 
Lot: …..  Expiration date: ……. 
 
 
 
Store at roomtemperature  
 
 
Exclusively for clinical research 
 
 
 
5.2.3.  
Storage 
The -Olive oil (oral ampoules) will be stored at room temperature, below 25°C. 
Temperature (minimum and maximum temperature) is recorded electronically every 
working day. 
5.2.4. Transfer 
After release by a responsible person, the IMP’s can be transferred to the principal 
investigator of each site, using a signed transfer document.  IMP will not be transferred 
to another site.  
5.2.5 Use, accountability and destruction 
See active product 
6. ADVERSE EVENTS AND CLINICAL EVENTS 
6.1. 
Definitions 
6.1.1. Adverse event 
An adverse event (AE) is defined as any untoward medical occurrence in a patient 
administered an investigational medicinal product and which does not necessarily 
have a causal relationship with this treatment. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 40 of 52 
# 
 
6.1.2. Serious and non-serious adverse events 
All AEs fall into either the category “non-serious” or “serious”. A serious adverse event 
(SAE) is any untoward medical occurrence that at any dose: 
▪ 
Results in death 
▪ 
Is life-threatening 
▪ 
Requires inpatient hospitalisation or prolongation of existing hospitalisation 
▪ 
Results in persistent or significant disability or incapacity 
▪ 
Is a congenital anomaly or birth defect 
▪ 
Is an important medical event 
A non-serious adverse event is any untoward medical occurrence that does not fulfil 
any of the criteria listed above. 
Adverse events with respect to abnormal assay results and precautionary safety 
procedures to be taken: 
- 
Clinical significant hypercalcemia: defined as 2 independent measurements (2 
different laboratories), above the reference value; action taken: end of study 
- 
HypervitaminoseD: defined as 25(OH)D3 > 80 ng/ml; action taken: discontinue 
study drug and restart monthly treatment with study drug when 25(OH)D3 falls below 
50 ng/ml on 3 monthly monotoring .   
- 
Hypovitaminose D: 
 
 
* 
Serum 
25(OH)D3 
< 
10 
ng/ml 
at 
baseline; 
 
action 
taken:  
supplementation of extra vitamin (D-cure): 25000IU / month,  
* Serum 25(OH)D3 < 10 ng/ml at 6 months or later;  action taken: end-
of-study 
 
 
* Serum 25(OH)D3 > 10 ng/ml and < 20 ng/ml at baseline: 
supplementation of extra vitaminD (D-cure): 25000IU/month 
* Serum 25(OH)D3 > 10 ng/ml and < 20 ng/ml at 6 months or later: 
supplementation of extra vitaminD (D-cure): 25000IU/month 
- 
Hypophosphatemiae: < 1.5 mg/dl:   further investigation 
- 
Hyperphosphatemia: > 6mg/dl: further investigation 
Clarification of the difference in meaning between “severe” and “serious” 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 41 of 52 
# 
The term “severe” is often used to describe the intensity (severity) of a specific event 
(see next section below); the event itself, however, may be of relatively minor medical 
significance (such as severe headache). This is not the same as “serious”, which is 
based on the outcome or action criteria usually associated with events that pose a 
threat to life or functioning. Seriousness (not severity) serves as a guide for defining 
regulatory reporting obligations. 
6.1.3. Severity assessment 
The investigator will use the following terms to assess the severity of the adverse event: 
Mild:  
Causing no limitation of usual activities; the patient may 
experience slight discomfort 
Moderate: 
Causing some limitation of usual activities; the patient may 
experience annoying discomfort 
Severe: 
 
Causing inability to carry out usual activities; the patient 
may experience intolerable discomfort or pain 
6.1.4. Causality assessment 
The investigator will use the following causality terms to assess the relationship of the 
adverse event or clinical efficacy event to the use of the investigational medicinal 
product: 
Reasonable 
causal 
relationship 
with the investigational medicinal 
product: 
 
 
There is evidence or argument to suggest a 
causal relationship with the investigational 
medicinal product administered 
 
No reasonable causal relationship 
with the investigational medicinal 
product: 
 
There is no evidence or argument to suggest a 
causal relationship with the investigational 
medicinal product administered 
Similarly, the investigator will assess the relationship of the AE/CE to the therapy 
associated interventions. 
6.2. 
Clinical handling 
During and after a patient's participation in the trial, the investigator needs to ensure 
that adequate medical care is provided to a patient for any AE, including clinically 
significant laboratory values, or CE. The investigator should inform a patient when 
medical care is needed for concurrent illness of which the investigator becomes aware.  
All SAEs that occur in the course of a clinical study regardless of the causal 
relationship must be monitored and followed up until the outcome is known. There 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 42 of 52 
# 
must be documented reasonable attempts to get this information. It is the 
responsibility of the investigator to ensure that any necessary additional therapeutic 
measures and follow-up procedures are performed. The clinical course of the AE/CE 
will be followed up according to accepted standards of medical practice, even after the 
end of the period of observation until a satisfactory explanation is found or the 
investigator considers it medically justifiable to terminate follow-up. 
6.3. 
Collection period 
In this study, the collection period for serious adverse events starts at randomisation 
and ends when the patient completes the study or at premature termination.  
6.4. 
Documentation and reporting 
6.4.1. Documentation of SAEs 
The investigator must document all SAEs that occur during the observation period in 
the SAE module provided in the eCRF. Every attempt should be made to describe all 
SAEs in terms of a diagnosis. If a clear diagnosis has been made, individual signs and 
symptoms should not be recorded unless they represent atypical or extreme 
manifestations of the diagnosis, in which case they should be reported as separate 
events. If a clear diagnosis cannot be established, signs and symptoms must be 
recorded individually. 
6.4.2. Documentation and reporting of SAEs 
If the AE is serious, the investigator must complete an “eSAE Report Form” at the time 
the SAE is detected. This form must be provided immediately, i.e. within one working 
day upon becoming aware of the SAE to the SAE processing centre. 
The SAE initial report should be as complete as possible, including details of the 
current illness and the serious AE, the reason why the event was considered serious, 
date of onset and stop date (if applicable), diagnostic procedures and treatment of the 
event, relevant medical history and concomitant medication and action taken with 
investigational medicinal product (if applicable). 
Information not available at the time of the initial report (e.g., an end date for the SAE 
or laboratory values received after the report) must be documented and reported as a 
follow up. Should the SAE result in death, a full pathologist’s report should be 
supplied, if possible. 
The SAE processing centre will identify missing information for each reported SAE. 
Requests for follow up will be sent for further processing to the investigator. Follow up 
information are required at regular intervals from the investigators until all queries are 
resolved or no further information can be reasonably expected. All responses to queries 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 43 of 52 
# 
and supply of additional information by the investigator should follow the same 
reporting route as the initial report and must be sent without delay. 
6.4.3. Reporting of serious adverse events to competent authorities and 
concerned ethics committees 
A SUSAR (suspected unexpected serious adverse reaction) is an AE that is: 
▪ 
serious and  
▪ 
unexpected (meaning that nature or severity of the AE is not consistent with the 
IMP reference safety information, which is the Investigator’s Brochure) and 
▪ 
is judged by either the investigator or the sponsor as having a reasonable 
suspected causal relationship with the investigational medicinal product.  
SUSARs are subject to expedited reporting. The sponsor reports all SUSARs to the 
Competent Authority and the concerned Ethic Committee according to applicable 
regulations and timelines.  
The sponsor also prepares and submits annual safety reports to Competent Authority 
and Ethics Committee. 
6.4.4. Documentation of abnormal laboratory values 
Abnormal laboratory parameters per se will not be recorded as adverse events. They 
will only be reported as AEs if the deviation from the normal range is assessed as 
“clinically significant” by the investigator and/or when they result in precautionary 
safety measures. All other abnormal laboratory values will be documented and will 
only be considered within the context of an event which constitutes an AE. 
The following laboratory values will be reported as adverse events: 
Hypercalcemia: defined as 2 independent measurements (2 different laboratories) 
above the reference value. 
Hypervitaminose D: defined as serum 25(OH)D3 level > 80 ng/ml 
Hypovitaminose D: 
Deficient: serum 25(OH)D3 < 10 ng/ml 
Insufficient: serum 25(OH)D3 >10 ng/ml and < 20 ng/ml 
- 
Hypophosphatemiae: < 1.5mg/dl 
- 
Hyperphosphatemia: > 6mg/dl  
 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 44 of 52 
# 
6.4.5. Documentation and reporting of IMP exposure during pregnancy or 
lactation 
In principle, pregnancy and the lactation period are exclusion criteria. In the event of a 
pregnancy occurring during the course of this study, the study should be ended and 
the patient should be closely followed-up during the entire course of the pregnancy 
and postpartum period. When a pregnancy is detected without an adverse outcome, 
the investigator should complete a report and send this to the SAE processing centre 
without delay. It should be clearly stated that no AE was observed. In this case, there 
is no need to complete the AE module in the eCRF. Parental and neonatal outcomes 
must be recorded even if they are completely normal and without AEs. Off-spring 
should be followed up for at least 8 weeks after delivery. All serious or non-serious 
adverse events associated with the pregnancy will be handled as described in the 
previous sections 
7. STATISTICAL METHODS 
7.1. 
Sample Size 
Approximately 500 patients for the treatment group and for the control group are 
required. Assuming similar times to relapse as retrospectively observed at the 
University hospital Leuven, 3 year of recruitment and a total study duration of 3.5 
years, 500 patients will have 90% power to detect a hazard ratio of 0.40 in favour of 
the vitamin D supplemented arm by means of Cox proportional hazards model 
stratified for time since diagnosis (3 strata: 0, 6 or 12 months ago). The hazard ratio of 
0.40 is in correspondence with the intermediate effect size that was reported by 
Newton-Bishop et al (2009) and a potential increase in VD serum levels of 70 nmol/L 
which is 80% of the observed effect in a study with CPOD patients (Lehouck et al, 
2012). It is anticipated that no patient will be lost for follow-up. 
7.2. 
Statistical Methods 
The primary analysis is an intent-to treat analysis of all randomised patients. Patients 
will be analysed according to the treatment group to which they were randomised, 
irrespective of which study drug was given or if any study drug was received. 
Additional populations like a per protocol population may be defined in the statistical 
analysis plan 
The difference in relapse-free survival will be compared between the two treatment 
groups by means of a Cox proportional hazards model stratified for time since 
diagnosis (3 strata: 0, 6 or 12 months ago). It will be verified whether the treatment 
effect is stratum dependent. If so, the strata will be analysed separately. Furthermore, 
using a Cox proportional hazards model it will be investigated whether the potential 
treatment effect is different for VDR immunoreactivity and genetic variability in the 
Vitamin D pathway. A correction for other baseline covariates like gender, age and 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 45 of 52 
# 
baseline Vitamin D level will be performed as sensitivity analyses.  No interim analysis 
for efficacy is foreseen. Potential subgroups analysis like for instance calcium serum 
levels will be defined in the statistical analysis plan 
The evolution in 25(OH)D3 levels in function of genetic variability in the Vitamin D 
pathway will be analysed by a linear mixed model. Sensitivity analyses will include 
patient’s compliance, seasonal effects and patient’s baseline characteristics like age 
and gender. 
In order to examine the effect of the actual 25(OH)D3 levels rather than just 
supplementation, the evolution of 25(OH)D3 levels and relapse-free survival will be 
jointly modelled. 
The potential correlation between VDR immunoreactivity and stage at diagnosis will be 
assessed by means of a Kruskal Wallice test. 
The potential correlation between vitamin D levels at diagnosis with melanoma site and 
melanoma subtype will be assessed by means of an analysis of variance. This analysis 
can only be performed for newly diagnosed patients because vitamin D levels at 
diagnosis will not be available for patients who had their diagnosis 6 or 12 months ago. 
Full details of the statistical analyses will be described in a statistical analysis plan 
which will be finalized before database lock. 
8. ETHICAL, ADMINISTRATIVE AND LEGAL ASPECTS 
8.1. 
Ethical conduct of the study and informed consent 
The study is conducted according to the protocol and in strict compliance with ICH 
GCP, the Declaration of Helsinki and all applicable regulatory requirements.  
Before the start of the study, the study protocol, the investigator brochure and other 
applicable documents are submitted to an independent Ethics Committee (EC) and 
responsible national and local authority, as required by the participating country 
regulation. The study can start only after a favourable EC opinion and a regulatory 
authorisation has been obtained. The sponsor informs the investigator in writing that 
all ethical and legal requirements have been met before the first patient is enrolled in 
the study. After the protocol has been accepted, substantial amendments to this 
protocol require the corresponding assessment processes by competent authorities 
and/or ECs as described above. After the end of the study, a final study report is 
prepared and distributed to regulatory authorities and ECs as required by applicable 
regulations. 
Before a patient can participate in the study, patient’s informed consent needs to be 
obtained according to GCP and the legal requirements of the country concerned.  
Patient information sheet and consent form must have been reviewed and approved by 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 46 of 52 
# 
the responsible EC. The investigator or an authorised designate explains the nature, 
purpose, scope and course of the study, including information on the investigational 
medicinal product, potential benefits and risks to the patient. In addition to oral 
information, the patient receives a written patient information sheet containing all 
relevant information. Sufficient time will be allowed to discuss any questions raised. 
Only after this process is completed, consent for participation may be given. Consent 
must be obtained prior to any study specific procedure and with sufficient time before 
a study related intervention as per local requirements. The consent form must be 
personally signed and dated by the individual giving consent and by the investigator or 
designee who lead the informed consent process with the patient. The consent form 
must be retained by the investigator as part of the study records. In addition, the 
patient receives a copy of the patient information sheet and a copy of his/her signed 
and dated consent form. Confirmation that consent was obtained is also documented 
in the medical records and on the eCRF. Should a protocol amendment be made, the 
patient information sheet may need to be revised to reflect the change(s) of the 
protocol. After the EC has approved the revised information sheet and consent form, it 
is the responsibility of the investigator to inform all active patients affected by the 
change, and to receive their written consent for continuation in the study.  
All patients must be identifiable throughout the study at the study site. The 
investigator will maintain a personal list of patient numbers and patient names for 
data reconciliation. 
8.2. 
Study-specific committees 
8.2.1. Study Executive Committee 
An Executive Committee is appointed. This smaller body provides a more rapid 
management body for day to day or operational level decision and consultation. The 
functions of the Executive Committee are to prepare, update, and maintain the trial 
protocol and corresponding forms, review performance reports of the clinical centres, 
resolve operational problems and to supervise data preparation, data analysis and 
publication of study reports. 
8.2.2. Data & Safety Monitoring Board 
An independent Data and Safety Monitoring Board (DSMB) is formed to monitor 
patient safety as the study progresses. The DSMB has been selected by and 
communicates directly to the study’s Executive Committee. The DSMB is authorised to 
make recommendations to the Executive Committee and sponsor regarding safety 
issues. If a serious concern with the safety of the patients in the trial would arise, the 
DSMB may recommend early termination of the study. Working procedures governing 
the convening, execution and the responsibilities of the DSMB are specified separately 
in a prospectively written charter. The DSMB should initially review safety issues every 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 47 of 52 
# 
three months. The review includes, but may not be limited to, unexpected serious 
adverse events, mortality and complications of high dose vitamin D supplementation 
8.2.3. Clinical endpoint committee 
Endpoints will be reported as occurring throughout the follow up. Defined endpoints 
are adjudicated by an independent Clinical Endpoint Committee (CEC) blinded to the 
patient treatment allocation, ensuring a consistent and unbiased adjudication of 
events 
8.3. 
Case report forms 
All case report forms will be electronic using Open Clinica, a web-based tool, provided 
by LCC. The site staff will enter and edit the data via a secure network, with secure 
access. An electronic audit trail will be maintained. The investigator will confirm the 
accuracy of the data by using an electronic signature. 
8.4. 
Quality control 
8.4.1. Study monitoring and inspections 
All efforts will be done to reassure maximal quality control. Study will be performed 
according GMP. Direct access to source data is available. Access is carried out with 
strict adherence to all confidentiality regulations. 
8.5. 
Confidentiality 
All local legal requirements regarding data protection must be adhered. All study 
documents and study findings are regarded as confidential. The confidentiality of 
patients participating in the study must be maintained. Throughout documentation 
and evaluation, the patients are identified on eCRFs and other documents that are 
transferred outside the study centre by their patient number. Documents identifying 
the patient (e.g. the signed informed consent, health records) must be maintained 
confidential by the investigator.  
8.6. 
Use of records and archiving 
8.6.1. Publication and use of study findings 
The Parties agree that publications or presentations of any of the results from the 
Study shall be in accordance with accepted scientific practice, academic standards and 
customs.   
The Parties agree that at first they will strive to make a joint publication coordinated 
by Sponsor. After such joint publication the following shall be agreed: 
As a general principle, the Parties agree that prior to submission of a publication or 
any other dissemination of the results, including oral presentation, the Sponsor shall 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 48 of 52 
# 
have the right to prior review and comments on the content of the material to be 
published or presented. Sponsor may request, within thirty (30) days following the 
receipt of the publication or any other dissemination of the results, that Sponsor’s 
confidential information would be deleted before proceeding with the publication or 
any dissemination of the results. 
Authorship and other related publications questions shall be addressed in accordance 
with the principles of the ‘Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals’ and in accordance with the requirements of the respective 
medical journal 
  
8.6.2. Archiving of study records 
Essential documents should be retained according to the legal requirements 
8.7. 
Insurance/Indemnity 
Sponsor shall be liable, even without fault, for any damages incurred by a Study 
Patient and linked directly or indirectly to the participation to the Study. 
Sponsor shall enter into an insurance agreement in order to cover the liability for any   
damages incurred by a Study Patient included in the Belgian participating site. 
If an insurance coverage is required by local laws of non-Belgian Participating Sites, 
these Participating Sites shall have and maintain in full force and effect during the 
term of this Agreement (and following termination of the trial to cover any claims 
arising from the trial) adequate insurance coverage for possible damages linked directly 
or indirectly to the patients’ participation to the trial at Participating Sites. 
8.8. 
Financial Aspects 
There is partial funding of the study by the Belgian agency for science and technology 
(Agentschap voor Innovatie door Wetenschap en Technologie – IWT), Het Anti-
Kankerfonds and Kom op Tegen Kanker. 
 
 
9. REFERENCES 
Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010 
Feb;95(2):471-8. 
Asgari MM, Maruti SS, Kushi LH, White E. A cohort study of vitamin D intake and 
melanoma risk. J Invest Dermatol. 2009 Jul;129(7):1675-80. Epub 2009 Feb 5. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 49 of 52 
# 
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, 
Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, 
McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version 
of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 
20;27(36):6199-206. Epub 2009 Nov 16. 
Bataille V, de Vries E. Melanoma--Part 1: epidemiology, risk factors, and prevention. 
BMJ. 2008 Nov 20;337:a2249. doi: 10.1136/bmj.a2249. 
Belgian Cancer Registry. Cancer Incidence in Belgium 2004-2005. 
Belgian Cancer Registry. Cancer incidence in Belgium 2008. 
Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, Randerson-Moor J, 
Aitken JF, et al. 
Genome-wide association study identifies three loci associated with melanoma risk. 
Nat Genet. 2009 Aug;41(8):920-5. Epub 2009 Jul 5. 
Bishop JN, Bataille V, Gavin A, Lens M, Marsden J, Mathews T, Wheelhouse C. The 
prevention, diagnosis, referral and management of melanoma of the skin: concise 
guidelines. Clin Med. 2007 Jun;7(3):283-90. 
Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct 
subtypes of melanoma. J Clin Oncol. 2006 Sep 10;24(26):4340-6. 
De Haes P, Garmyn M, de Greef H, Vantieghem K, Bouillon R, Segaert S. 1,25-
dihydroxyvitamin D3 and two low-calcemic analogues protect keratinocytes against 
UVB-induced damage. J Photochem Photobiol B , (2005) feb; 1;78 (2): 141-8.  
Egan KM. Vitamin D and melanoma. Ann Epidemiol. 2009 Jul;19(7):455-61. Epub 
2009 Mar 17. 
Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, Pastinen T, Cervino A, Zhao 
ZZ, Deloukas P, 
Soranzo N, Elder DE, Barrett JH, Martin NG, Bishop DT, Montgomery GW, Spector TD. 
Genome-wide 
 association study identifies variants at 9p21 and 22q13 associated with development 
of cutaneous nevi.  
Nat Genet. 2009 Aug;41(8):915-9.   
Gandini S, Raimondi S, Gnagnarella P, Doré JF, Maisonneuve P, Testori A. Vitamin D 
and skin cancer: a meta-analysis. Eur J Cancer. 2009 Mar;45(4):634-41. Epub 2008 
Nov 12. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 50 of 52 
# 
Garbe C, Leiter U. Melanoma epidemiology and trends. Clinics in Dermatology. 
2009:27;3-9. 
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob JJ, Malhevy J, 
Newton-Bishop J, Stratigos A, Pehamberger H, Eggermont A. Diagnosis and treatment 
of melanoma. European consensus-based interdisciplinary guideline_Update 2012. 
Eur J Cancer. 2012 48:2375-2390Gupta R, Dixon KM, Deo SS, Holliday CJ, Slater M, 
Halliday GM, Reeve VE, Mason RS. Photoprotection by 1,25 dihydroxyvitamin D3 is 
associated with an increase in p53 and a decrease in nitric oxide products. J Invest 
Dermatol. 2007 Mar;127(3):707-15. Epub 2006 Dec 14. 
Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo 
Clin Proc. 2006 Mar;81(3):353-73. 
Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, Jones PW, 
York C, Strange RC, Fryer AA. Vitamin D receptor polymorphisms are associated with 
altered prognosis in patients with malignant melanoma. Clin Cancer Res. 2000 
Feb;6(2):498-504. 
Janssens W, Bouillon R, art Claes et al. Vitamin D deficiency is highly prevalent in 
COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010 65: 
215-220. 
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. CA Cancer J Clin. 2008 
Mar-Apr;58(2):71- 
96. Epub 2008 Feb 20. Cancer statistics, 2008. 
Lambrechts D, Buysschaert I, Zanen P, Coolen J, Lays N, Cuppens H, Groen HJ, 
Dewever W, van Klaveren RJ, Verschakelen J, Wijmenga C, Postma DS, Decramer M, 
Janssens W. The 15q24/25 susceptibility variant for lung cancer and chronic 
obstructive pulmonary disease is associated with emphysema. Am J Respir Crit Care 
Med. 2010 Mar 1;181(5):486-93. Epub 2009 Dec 10. 
Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, Van Eldere J, Decallone 
B, Bouilon R, Decramer M, Janssens W. High doses of Vitamin D to reduce 
exacerbations in Chronis Obstroctive Pulmonary Disease: a randomized trial. Annals of 
Internal medicine. ; 2012; 156: 105-114.  
Lee DM, Rutter MK, O'Neill TW, Boonen S, Vanderschueren D, Bouillon R, Bartfai G, 
Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean 
ME, Pendleton N, Punab M, Silman AJ, Wu FC; European Male Ageing Study Group. 
Vitamin D, parathyroid hormone and the metabolic syndrome in middle-aged and older 
European men. Eur J Endocrinol. 2009 Dec;161(6):947-54. Epub 2009 Sep 22. 
Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006 Jul 6;355(1):51-65. 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 51 of 52 
# 
Mohr P, Eggermont AMM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. 
Annals of Oncology (Supplement 6): vi14-vi21, 2009,  
Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, 
Chan M, Leake S, Karpavicius B, Haynes S, Kukalizch K, Whitaker L, Jackson S, Gerry 
E, Nolan C, Bertram C, Marsden J, Elder DE, Barrett JH, Bishop DT. Serum 25-
hydroxyvitamin D3 levels are associated with breslow thickness at presentation and 
survival from melanoma. J Clin Oncol. 2009 Nov 10;27(32):5439-44. Epub 2009 Sep 
21. 
Norman AW, Bouillon R. Vitamin D nutritional policy needs a vision for the future. Exp 
Biol Med (Maywood). 2010 Sep;235(9):1034-45. Epub 2010 Jul 28. 
Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, Tilgen W, 
Reichrath J. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma 
patients. Anticancer Res. 2009 Sep;29(9):3669-74. 
Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to 
malignant melanoma? Br J Dermatol. 2002 Aug;147(2):197-213. 
Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, Affleck P, 
Leake S, Haynes S, Karpavicius B, Marsden J, Gerry E, Bale L, Bertram C, Field H, 
Barth JH, Silva Idos S, Swerdlow A, Kanetsky PA, Barrett JH, Bishop DT, Bishop JA. 
Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and 
melanoma: UK case-control comparisons and a meta-analysis of published VDR data. 
Eur J Cancer. 2009 Dec;45(18):3271-81. Epub 2009 Jul 15. 
Rhodes LE, Webb AR, Fraser HI, Kift R, Durkin MT, Allan D, O'Brien SJ, Vail A, Berry 
JL. Recommended summer sunlight exposure levels can produce sufficient (> or =20 
ng ml(-1)) but not the proposed optimal (> or =32 ng ml(-1)) 25(OH)D levels at UK 
latitudes. J Invest Dermatol. 2010 May;130(5):1411-8. Epub 2010 Jan 14. 
Sage RJ, Lim HW. Therapeutic Hotline: Recommendations on photoprotection and 
vitamin D. Dermatol Ther. 2010 Jan;23(1):82-5. 
Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, 
Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, 
Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de 
Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, 
Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, 
Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai G, 
Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, 
Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, 
Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, 
Järvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, 
Dupuis J, Hyppönen E, Spector TD. Common genetic determinants of vitamin D 

Vitamin D supplementation in cutaneous malignant melanoma outcome 
 05-01-2021 
Confidential                                             page 52 of 52 
# 
insufficiency: a genome-wide association study. Lancet. 2010 Jul 17;376(9736):180-8. 
Epub 2010 Jun 10. 
Weinstock MA, Stampfer MJ, Lew RA, Willett WC, Sober AJ. Case-control study of 
melanoma and dietary vitamin D: implications for advocacy of sun protection and 
sunscreen use. J Invest Dermatol. 1992 May;98(5):809-11. 
Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic 
nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer 
Inst. 2003 Jun 4;95(11):806-12.